iSpecimen (ISPC)
NASDAQ:ISPC
Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$3.05 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$4.41M
Enterprise Value-$2.13M
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$254.99K
Price to Earnings (P/E)―
Beta1.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,437,157
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-2.07
Enterprise Value/Gross Profit6.98
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Marketplace NetworkA two-sided, tech-enabled marketplace connecting buyers (pharma, biotech, academia) and suppliers creates durable network effects. Diversified buyer use cases and supplier breadth support recurring transaction fees and structural demand for curated human biospecimens across research cycles.
Operational LogisticsDirect shipment model materially shortens transit times, lowers costs and improves reliability. Deepened European sourcing access to rare biospecimens strengthens supplier reach and product differentiation, improving long-term service levels and competitiveness in complex specimen logistics.
Low Financial LeverageVery low debt reduces fixed financing obligations, giving management flexibility to raise or deploy capital without heavy interest burden. This balance-sheet conservatism supports continued operations and strategic investments while cash burn is addressed, lowering near-term solvency risk.
Bears Say
Sharp Revenue DeclineA steep, persistent drop in revenue undermines platform liquidity and unit economics that power marketplace dynamics. Reduced volumes impair margins, weaken supplier and buyer retention, and make durable recovery harder without sustained demand-restoration initiatives or significant customer wins.
Sustained Cash BurnConsistent negative operating cash flow and recurring negative free cash flow force reliance on external financing. Ongoing burn limits the company’s ability to invest in technology, sales, and logistics at scale and increases dilution risk if additional capital is required to sustain operations.
Listing & Governance RiskA formal noncompliance notice on minimum equity threatens continued Nasdaq listing, which can restrict access to public capital and distract management with compliance remediation. Coupled with recurring quorum shortfalls and incentive plan dilution, governance execution risk to strategic plans is elevated.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $3.05 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $4.41M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 1,437,157 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.42% Mutual Funds
― Other Institutional Investors
95.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---